Signals of progress

Ibogaine news

Momentum is building. These are the developments we consider genuinely encouraging for Boston, New England and the wider United States — funding decisions, legislative progress and peer-reviewed results. Every item links to its original source so you can read it in full and judge it yourself.

Boston & New England

· Psychedelic Alpha

Harvard awarded an $11M NIDA grant for ibogaine research in opioid use disorder

The National Institute on Drug Abuse funded a multi-phase ibogaine project at Harvard — the clearest sign yet that this work is moving into mainstream federally funded science in the Boston area.

· The Boston Globe

Boston Globe opinion: psychedelic therapy could save veterans' lives

The founders of Veterans Exploring Treatment Solutions argue the moment for psychedelic medicine has arrived, citing the 2024 Stanford results in veterans.

· GBH News

GBH: ibogaine is gaining ground in the treatment of addiction and PTSD

Boston public radio covers the federal executive order aimed at accelerating review and research of psychedelics, with ibogaine specifically highlighted.

· South Shore Senior News

Beacon Hill hears veterans and clinicians on psychedelic therapy

Testimony from veterans and medical experts preceded committee votes on H.4200 and H.2203, signalling growing legislative momentum in Massachusetts.

· Boston Institute for Nonprofit Journalism

Massachusetts lawmakers advance psychedelic therapy bills covering ibogaine

Two bills advanced out of the Joint Committee on Mental Health, Substance Use and Recovery, raising the prospect of a state programme for ibogaine and psilocybin.

· Boston magazine

Boston magazine: what's the deal with ibogaine?

A local primer on the promise and the perils of ibogaine, published as Massachusetts voters weighed the Question 4 psychedelics ballot measure.

United States

Research

A note on balance

Encouraging headlines do not remove the risks. Strictly for informational and research purposes. Not medical advice. Ibogaine carries serious cardiac risk and requires qualified medical screening and continuous supervision.

Send an enquiry